Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960633 | 0.89 | GAA (0.38) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL101218 | 0.88 | DGAT1 (0.46) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL12246341 | 0.87 | CA1 (0.39) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL1522412 | 0.86 | DGAT1 (0.44) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL6272856 | 0.86 | DGAT1 (0.44) | DGAT1TDP1NFKB1NFKB2RELA | |
| Potassium SCHEMBL29554503 | 0.86 | DGAT1 (0.44) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL22063661 | 0.82 | CTSK (0.44) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL3755352 | 0.81 | DGAT1 (0.41) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL3509747 | 0.81 | DGAT1 (0.46) | DGAT1TDP1NFKB1NFKB2RELA | |
| SCHEMBL3951511 | 0.81 | APLNR (0.41) | DGAT1TDP1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101904-A1 | NOREPINEPHRINE TRANSPORTER-TARGETED PRODRUGS FOR CANCER THERAPY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-05-15 | — | — | WO | disclosed |
| CN-116234806-A | Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116034106-A | Cyclic 2-amino-3-cyanothiophenes and derivatives for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-114901652-A | Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-08-12 | — | — | CN | disclosed |
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2014138484-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | DGAT1 1917/4885TDP1 1948/4885NFKB1 2084/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | DGAT1 4627/4885TDP1 3546/4885NFKB1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.